US Stock MarketDetailed Quotes

INCY Incyte

Watchlist
  • 70.420
  • +0.410+0.59%
Close Feb 14 16:00 ET
  • 69.000
  • -1.420-2.02%
Post 20:01 ET
13.63BMarket Cap469.47P/E (TTM)

About Incyte Company

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Company Profile

SymbolINCY
Company NameIncyte
Listing DateNov 4, 1993
Issue Price7.50
Founded1991
CEOMr. Herve Hoppenot
MarketNASDAQ
Employees2617
Fiscal Year Ends12-31
Address1801 Augustine Cut-Off
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19803
Phone1-302-498-6700
Websitehttp://www.incyte.com

Company Executives

  • Name
  • Position
  • Salary
  • Herve Hoppenot
  • Chairman of the Board, President and Chief Executive Officer
  • 16.66M
  • Thomas Tray
  • Vice President and Chief Accounting Officer
  • --
  • Christiana Stamoulis, M.B.A.
  • Executive Vice President and Chief Financial Officer
  • 5.08M
  • Dr. Steven H. Stein, M.D.
  • Executive Vice President and Chief Medical Officer
  • 5.63M
  • Matteo Trotta
  • Executive Vice President and General Manager, Dermatology US
  • --
  • Barry P. Flannelly, Pharm.D.
  • Executive Vice President and General Manager, North America
  • 4.09M
  • Mohamed Khairie Issa
  • Executive Vice President and Head of US Oncology
  • --
  • Sheila A Denton
  • Executive Vice President, General Counsel and Corporate Secretary
  • --
  • Michael James Morrissey
  • Executive Vice President and Head of Global Technical Operations
  • --
  • Vijay K. Iyengar
  • Executive Vice President, Global Strategy and Corporate Development
  • --
  • Lee Heeson
  • Executive Vice President, Incyte International
  • --
  • Paula J. Swain
  • Executive Vice President, Human Resources
  • --
  • Dr. Pablo J. Cagnoni, M.D.
  • President and Head of Research and Development
  • 15.83M
  • Paul J. Clancy
  • Independent Director
  • 479.76K
  • Dr. Katherine A. High, M.D.
  • Independent Director
  • 454.76K
  • Dr. Otis W. Brawley,M.D.
  • Independent Director
  • 454.76K
  • Dr. Susanne Schaffert, PhD
  • Independent Director
  • 444.76K
  • Julian C. Baker
  • Lead Independent Director
  • 512.76K
  • Dr. Edmund P. Harrigan, M.D.
  • Independent Director
  • 482.26K
  • Dr. Jacqualyn A. Fouse, PhD
  • Independent Director
  • 466.26K
  • Jean-Jacques Bienaime
  • Independent Director
  • 478.76K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Trump's comeback to the Office
Following Trump's Policies to Seek Investment Opportunities
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call